Short communication, Note

https://doi.org/10.24869/psyd.2022.171

ANTI-DEPRESSANTS AND COVID-19: A NEW RAY OF HOPE

Erum Khan ; B.J. Medical College and Civil Hospital, Ahmedabad, India
Ishan Jani orcid.org/0000-0002-3792-5950 ; B.J. Medical College and Civil Hospital, Ahmedabad, India
Mainak Bardhan orcid.org/0000-0002-4106-409X ; Department of Neurology, National Institute of Mental Health and Neurosciences (NIMHANS), Bengaluru, Karnataka, India ; ICMR- National Institute of Cholera and Enteric Diseases (NICED), Kolkata India
Mohammad Mehedi Hasan orcid.org/0000-0002-3871-889X ; Department of Biochemistry and Molecular Biology, Faculty of Life Science, Mawlana Bhashani Science and Technology University, Tangail, Bangladesh ; Division of Infectious Diseases, The Red-Green Research Centre, BICCB, Dhaka, Bangladesh

Abstract

The coronavirus disease pandemic has grown worldwide. As we understand the exact pathophysiology of the disease and how it
affects the systems in the human body, we are in the process of discovering and repositioning drugs potentially effective in these
regards. A few targets of these drugs are excessive inflammation following SARS-CoV-2 infection and sigma-1 receptor ER chaperone
protein, which plays a role in replication. The recent discovery of antidepressants like fluvoxamine and clomipramine acting through
these targets may provide a new ray of hope to decrease mortality and morbidity in severe COVID patients.

Keywords

antidepressants; COVID-19 pandemic; drug repositioning; SSRI; SNRI

Hrčak ID:

277532

URI

https://hrcak.srce.hr/277532

Publication date:

3.5.2022.

Visits: 620 *